Semaglutide is a once-weekly injection (eg, Ozempic) that is typically used to treat type 2 diabetes
Food & Drug Administration (2025) Ozempic, DailyMed (2025) Wegovy, DailyMed (2024) Once-weekly semaglutide in adults with overweight or obesity, New England Journal of Medicine (2021) Vitamin B12, National Institutes of Health Office of Dietary Supplements (2024) Vitamin B12 injections: What they can and cant do, Cleveland Clinic (2024) Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes, Obesity Pillars (2024) Inverse association between serum vitamin B12 concentration and obesity among adults in the United States, Frontiers in Endocrinology (Lausanne) (2019) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
This article reviews current research, clinical guidance, and practical considerations for patients and healthcare providers
Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting
(CBT article summarizing methylene blue contraindication in G6PD deficiency) (NCBI) Turner, L
The two drug classes share the goal of weight loss but achieve it through fundamentally different biological pathways, which is precisely why they have different efficacy profiles, side effects, and treatment durations
